# PHASE 1 CLINICAL TRIAL UNITS FOR THERAPEUTICS: CHIKUNGUNYA VIRUS

> **NIH NIH N01** · DUKE UNIVERSITY · 2022 · $1,386,229

## Abstract

The Phase I Clinical trial units provide resources for the development and implementation of Phase I trials to investigate therapeutic agents for the treatment of infectious diseases. The units will investigate therapeutic agents for viral (other than HIV), bacterial, fungal and parasitic diseases including NIAID priority biodefense pathogens and emerging and re-emerging diseases. The Phase I units provide an invaluable vehicle for the investigation of new therapeutic and immunomodulatory agents for the treatment of infectious disease.

## Key facts

- **NIH application ID:** 10593884
- **Project number:** 272201500006I-P00006-759301900131-1
- **Recipient organization:** DUKE UNIVERSITY
- **Principal Investigator:** ROB CAUDLE
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,386,229
- **Award type:** —
- **Project period:** 2019-06-07 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10593884

## Citation

> US National Institutes of Health, RePORTER application 10593884, PHASE 1 CLINICAL TRIAL UNITS FOR THERAPEUTICS: CHIKUNGUNYA VIRUS (272201500006I-P00006-759301900131-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10593884. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*